Enliven Therapeutics (ELVN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
ELVN slides 5.1% to $37.32, a 3-month low. Closed at $37.32, -5.11% vs the prior close of $39.33. Day range $36.96–$39.47, opened at $39.33.
ELVN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ELVN slides 5.1% to $37.32, a 3-month low
- Closed at $37.32, -5.11% vs the prior close of $39.33. Day range $36.96–$39.47, opened at $39.33.
- Volume was 1.19M shares, 1.0x its 50-day average of 1.19M.
- Price is -28.3% vs its 50-day average ($52.04) and -10.3% vs its 200-day average ($41.62).
- 52-week range $14.78–$62.32; today's close sits at 47% of that range, 40.1% below the 52-week high.
Oct 15, 2026 — ELVN ends flat (+0.1%) to $39.33
- Closed at $39.33, +0.13% vs the prior close of $39.28. Day range $38.49–$40.29, opened at $39.48.
- Volume was 2.05M shares, 1.7x its 50-day average of 1.19M.
- Price is -25.1% vs its 50-day average ($52.50) and -5.3% vs its 200-day average ($41.52).
- 52-week range $14.78–$62.32; today's close sits at 52% of that range, 36.9% below the 52-week high.
Oct 14, 2026 — ELVN dips 0.5% to $39.28, a 3-month low, 3 down days in a row
- Closed at $39.28, -0.53% vs the prior close of $39.49. Day range $38.51–$39.95, opened at $38.99.
- Volume was 1.22M shares, 1.0x its 50-day average of 1.21M.
- Price is -25.8% vs its 50-day average ($52.91) and -5.1% vs its 200-day average ($41.40).
- 52-week range $14.78–$62.32; today's close sits at 52% of that range, 37.0% below the 52-week high.
- That makes 3 straight losses.
- SEC filings that day: 8-K.
Oct 13, 2026 — ELVN slides 3.3% to $39.49, a 3-month low
- Closed at $39.49, -3.31% vs the prior close of $40.84. Day range $39.27–$40.99, opened at $40.56.
- Volume was 847.90K shares, 0.7x its 50-day average of 1.25M.
- Price is -26.0% vs its 50-day average ($53.34) and -4.3% vs its 200-day average ($41.28).
- 52-week range $14.78–$62.32; today's close sits at 52% of that range, 36.6% below the 52-week high.
Oct 12, 2026 — ELVN dips 0.3% to $40.84
- Closed at $40.84, -0.34% vs the prior close of $40.98. Day range $40.50–$41.41, opened at $40.67.
- Volume was 579.80K shares, 0.5x its 50-day average of 1.26M — lighter than usual.
- Price is -24.0% vs its 50-day average ($53.71) and -0.8% vs its 200-day average ($41.17).
- 52-week range $14.78–$62.32; today's close sits at 55% of that range, 34.5% below the 52-week high.
Oct 9, 2026 — ELVN rises 0.9% to $40.98
- Closed at $40.98, +0.86% vs the prior close of $40.63. Day range $40.29–$42.06, opened at $41.00.
- Volume was 1.00M shares, 0.8x its 50-day average of 1.25M.
- Price is -24.1% vs its 50-day average ($53.99) and -0.2% vs its 200-day average ($41.05).
- 52-week range $14.78–$62.32; today's close sits at 55% of that range, 34.2% below the 52-week high.
Oct 8, 2026 — ELVN dips 1.8% to $40.63, a 3-month low, 4 down days in a row
- Closed at $40.63, -1.76% vs the prior close of $41.36. Day range $39.25–$40.90, opened at $40.90.
- Volume was 1.65M shares, 1.3x its 50-day average of 1.23M.
- Price is -25.1% vs its 50-day average ($54.25) and -0.7% vs its 200-day average ($40.93).
- 52-week range $14.78–$62.32; today's close sits at 54% of that range, 34.8% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — ELVN dips 2.4% to $41.36, a 3-month low, 3 down days in a row
- Closed at $41.36, -2.43% vs the prior close of $42.39. Day range $41.04–$42.38, opened at $41.62.
- Volume was 1.46M shares, 1.2x its 50-day average of 1.22M.
- Price is -24.1% vs its 50-day average ($54.50) and +1.3% vs its 200-day average ($40.81).
- 52-week range $14.78–$62.32; today's close sits at 56% of that range, 33.6% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — ELVN slides 6.8% to $42.39, a 3-month low on 1.9x normal volume
- Closed at $42.39, -6.77% vs the prior close of $45.47. Day range $41.22–$45.60, opened at $45.38.
- Volume was 2.33M shares, 1.9x its 50-day average of 1.20M — unusually heavy trading.
- Price is -22.6% vs its 50-day average ($54.75) and +4.2% vs its 200-day average ($40.69).
- 52-week range $14.78–$62.32; today's close sits at 58% of that range, 32.0% below the 52-week high.
Oct 5, 2026 — ELVN slides 3.2% to $45.47
- Closed at $45.47, -3.19% vs the prior close of $46.97. Day range $45.23–$46.94, opened at $46.94.
- Volume was 821.50K shares, 0.7x its 50-day average of 1.19M.
- Price is -17.3% vs its 50-day average ($54.95) and +12.1% vs its 200-day average ($40.56).
- 52-week range $14.78–$62.32; today's close sits at 65% of that range, 27.0% below the 52-week high.
Oct 2, 2026 — ELVN rises 1.6% to $46.97
- Closed at $46.97, +1.64% vs the prior close of $46.21. Day range $45.92–$47.43, opened at $47.38.
- Volume was 1.12M shares, 1.0x its 50-day average of 1.18M.
- Price is -14.8% vs its 50-day average ($55.10) and +16.2% vs its 200-day average ($40.42).
- 52-week range $14.78–$62.32; today's close sits at 68% of that range, 24.6% below the 52-week high.
ELVN latest news & SEC filings
Every SEC filing by or about ELVN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 16, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Oct 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Garland J. Scott converted options/RSUs into 13,000 shares at $15.47 (≈$201.11K) on Oct 1, 2026; now holds 13,000
- Garland J. Scott sold 13,000 shares at $46.67 (≈$606.72K) on Oct 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hohl Benjamin converted options/RSUs into 3,982 shares at $14.85 (≈$59.13K) on Sep 17, 2026; now holds 44,018
- Hohl Benjamin sold 3,535 shares at $50.03 (≈$176.85K) on Sep 17, 2026; now holds 40,483
- Hohl Benjamin sold 2,194 shares at $50.72 (≈$111.27K) on Sep 17, 2026; now holds 38,289
- Hohl Benjamin sold 289 shares at $51.49 (≈$14.88K) on Sep 17, 2026; now holds 38,000
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Collins Helen Louise converted options/RSUs into 5,000 shares at $2.48 (≈$12.40K) on Sep 17, 2026; now holds 30,000
- Collins Helen Louise sold 2,916 shares at $50.03 (≈$145.89K) on Sep 17, 2026; now holds 27,084
- Collins Helen Louise sold 1,844 shares at $50.71 (≈$93.51K) on Sep 17, 2026; now holds 25,240
- Collins Helen Louise sold 240 shares at $51.48 (≈$12.36K) on Sep 17, 2026; now holds 25,000
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$32.48M (prior year -$25.34M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.49 (prior year -$0.49) ( vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 24, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 22, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade ELVN
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 3, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.10% (largest 6.8%).
- Liquidity: about 1.27M shares (≈$47.26M) trade per day on average.
- 52-week position: $37.32 vs a range of $14.78–$62.32 (47% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Benjamin Hohl sold 3,535 shares on Sep 17, 2026.
- Latest filings: 8-K Oct 14, 2026; 10-Q Aug 5, 2026; 8-K Aug 5, 2026.
- Share count: 73.27M shares outstanding (Jul 28, 2026), +23.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ELVN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 39.33 | 39.47 | 36.96 | 37.32 | 1.19M |
| Oct 15, 2026 | 39.48 | 40.29 | 38.49 | 39.33 | 2.05M |
| Oct 14, 2026 | 38.99 | 39.95 | 38.51 | 39.28 | 1.22M |
| Oct 13, 2026 | 40.56 | 40.99 | 39.27 | 39.49 | 847.90K |
| Oct 12, 2026 | 40.67 | 41.41 | 40.50 | 40.84 | 579.80K |
| Oct 9, 2026 | 41.00 | 42.06 | 40.29 | 40.98 | 1.00M |
| Oct 8, 2026 | 40.90 | 40.90 | 39.25 | 40.63 | 1.65M |
| Oct 7, 2026 | 41.62 | 42.38 | 41.04 | 41.36 | 1.46M |
| Oct 6, 2026 | 45.38 | 45.60 | 41.22 | 42.39 | 2.33M |
| Oct 5, 2026 | 46.94 | 46.94 | 45.23 | 45.47 | 821.50K |
| Oct 2, 2026 | 47.38 | 47.43 | 45.92 | 46.97 | 1.12M |
| Oct 1, 2026 | 46.29 | 47.22 | 45.70 | 46.21 | 944.90K |
| Sep 30, 2026 | 46.98 | 46.98 | 45.47 | 45.84 | 800.20K |
| Sep 29, 2026 | 46.01 | 46.87 | 45.40 | 46.51 | 1.26M |
| Sep 28, 2026 | 44.38 | 46.90 | 44.19 | 46.01 | 1.28M |
| Sep 25, 2026 | 45.54 | 45.77 | 44.17 | 44.75 | 963.80K |
| Sep 24, 2026 | 45.90 | 46.51 | 44.81 | 45.17 | 749.40K |
| Sep 23, 2026 | 47.84 | 48.03 | 45.66 | 46.09 | 1.55M |
| Sep 22, 2026 | 49.07 | 49.13 | 47.70 | 48.19 | 1.21M |
| Sep 21, 2026 | 49.45 | 49.51 | 47.98 | 48.87 | 2.28M |
About Enliven Therapeutics
Enliven Therapeutics (ELVN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BURLINGAME, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1672619.
ELVN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Rahul D. Ballal | Director | Feb 17, 2026 |
| Jake Bauer | Director | Feb 17, 2026 |
| Mika K Derynck | Director | Aug 6, 2026 |
| Richard A. Fair | PRESIDENT AND CEO | Dec 12, 2025 |
| J. Scott Garland | Director | Feb 17, 2026 |
| Rishi Gupta | Director | Feb 17, 2026 |
| Richard A. Heyman | Director | Feb 19, 2026 |
| Samuel Kintz | PRESIDENT AND CEO | Nov 19, 2025 |
| Lori Anne Kunkel | Director | Jul 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Helen Louise Collins | CHIEF MEDICAL OFFICER | Sep 21, 2026 |
| Richard A. Fair | PRESIDENT AND CEO | Dec 12, 2025 |
| Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sep 21, 2026 |
| Samuel Kintz | PRESIDENT AND CEO | Nov 19, 2025 |
| Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Feb 17, 2026 |
| Anish Patel | CHIEF OPERATING OFFICER | Feb 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 17, 2026 | Benjamin Hohl | Sale | 3,535 | $50.03 |
| Sep 17, 2026 | Benjamin Hohl | Sale | 2,194 | $50.72 |
| Sep 17, 2026 | Benjamin Hohl | Sale | 289 | $51.49 |
| Sep 17, 2026 | Benjamin Hohl | Sale | 3,535 | $50.03 |
| Sep 17, 2026 | Benjamin Hohl | Sale | 2,194 | $50.72 |
| Sep 17, 2026 | Benjamin Hohl | Sale | 289 | $51.49 |
| Sep 17, 2026 | Benjamin Hohl | Sale | 3,535 | $50.03 |
| Sep 17, 2026 | Benjamin Hohl | Sale | 2,194 | $50.72 |
| Sep 17, 2026 | Benjamin Hohl | Sale | 289 | $51.49 |
| Sep 17, 2026 | Benjamin Hohl | Sale | 3,535 | $50.03 |
| Sep 17, 2026 | Benjamin Hohl | Sale | 2,194 | $50.72 |
| Sep 17, 2026 | Benjamin Hohl | Sale | 289 | $51.49 |
| Sep 17, 2026 | Helen Louise Collins | Sale | 1,844 | $50.71 |
| Sep 17, 2026 | Helen Louise Collins | Sale | 2,916 | $50.03 |
| Sep 17, 2026 | Helen Louise Collins | Sale | 240 | $51.48 |
ELVN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-103.69M | -1.83 | $-70.30M |
| Dec 31, 2024 | — | $-89.02M | -1.89 | $-73.19M |
| Dec 31, 2023 | — | $-71.58M | -2.01 | $-61.27M |
| Dec 31, 2022 | — | $-37.66M | -12.05 | $-32.08M |
| Dec 31, 2021 | — | $-51.38M | -2.37 | $-46.77M |
Latest balance sheet: total assets $910.22M, total liabilities $15.07M, cash $135.50M (as of Jun 30, 2026).
ELVN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $59.70 |
| May 7, 2026 | 8-K Item 2.02 (results) | $40.29 |
| Mar 3, 2026 | 8-K Item 2.02 (results) | $28.75 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $20.30 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $19.99 |
| May 14, 2025 | 8-K Item 2.02 (results) | $19.89 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $20.29 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $25.80 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 14, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ELVN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.